Palestinian govt cancels deal with Israel for supply of 1 mn Covid vax

The Palestinian government on Friday announced cancellation of a deal with Israel relating to the supply of around one million doses of Pfizer Covid-19 vaccine

Pfizer vaccine
Pfizer vaccine
ANI Others
2 min read Last Updated : Jun 19 2021 | 8:55 AM IST

The Palestinian government on Friday announced cancellation of a deal with Israel relating to the supply of around one million doses of Pfizer (COVID-19) vaccine.

The cancellation came after the government found the doses fall short of meeting the technical criteria.

''After the technical teams of the Ministry of Health examined the first batch of the Pfizer vaccines that were received this evening from Israel, estimated at 90,000 doses, it was found that they do not conform to the specifications contained in the agreement, and accordingly, Prime Minister Mohammad Shtayyeh instructed the Minister of Health to cancel the agreement,'' WAFA news reported quoting government spokesman Ibrahim Melhem.

During a joint press conference with Health Minister Mai Alkaila, the official added that the first batch of the cancelled deal were returned to Israel.

Earlier on the day, Health Minister Mai Alkaila said that Palestine had received an offer from Pfizer to urgently obtain about one million Pfizer COVID-19 doses from Israel, provided that the manufacturer, at the end of this year, will hand over the same amount to the Israeli side that was initially supposed to be allocated to Palestine prior to the aforementioned Pfizer offer.

The ceasefire deal, between Israel and Palestine that was reached on May 21, was violated on June 16. Israel and Hamas concluded 11 days of fighting during which hundreds of rockets were launched from both Israel and Palestine sides. According to the Hamas-run Gaza Health Ministry, 253 Palestinians were killed during the fighting, including 66 children, while 13 Israelis, including a 5-year-old boy and a soldier, were killed.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccinePfizerIsrael-Palestine

First Published: Jun 19 2021 | 8:51 AM IST

Next Story